The combination of the MTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma

被引：0
|
作者：
Leleu, X.
O'Sullivan, G.
Jia, X.
Ngo, H.
Moreau, A. S.
Roccaro, A.
Hatjiharisi, F.
Hideshima, T.
Anderson, K.
Ghobrial, I.
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] CHRU, Immunol Lab, Serv Malad Sang, Lille, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：148 / 149
页数：2
相关论文
共 50 条
  • [21] Biomimetic platelet nanoparticles encapsulated with proteasome inhibitor bortezomib for multiple myeloma treatment
    Gao, Guangtao
    Xu, Yong
    Gan, Jingjing
    Cao, Xinya
    Dong, Xiaoqing
    Fang, Mengkun
    Du, Ying
    Xu, Peipei
    Che, Junyi
    Chen, Bing
    APL MATERIALS, 2023, 11 (12)
  • [22] Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells
    Ju, Donghong
    Xie, Youming
    MOLECULAR MEDICINE REPORTS, 2014, 10 (05) : 2609 - 2612
  • [23] The combination of the mTOR inhibitor rapamycin and protein kinase C inhibitors produces marked synergistic anti-myeloma effects
    Shalitin, Dror
    Share, Michael
    Campbell, Richard A.
    Steinberg, Jeffrey
    Sanchez, Eric
    Warg, Joseph
    Leuchter, Richard
    Li, Mingjie
    Wang, Cathy S.
    Chen, Haiming
    Berenson, James R.
    BLOOD, 2007, 110 (11) : 273B - 273B
  • [24] Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
    Chauhan, Dharminder
    Das, Deepika Sharma
    Ray, Arghya
    Richardson, Paul G.
    Trikha, Mohit
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
    Pei, XY
    Dai, Y
    Grant, S
    CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3839 - 3852
  • [26] Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Francis, Lanie K.
    Alsayed, Yazan
    Leleu, Xavier
    Jia, Xiaoying
    Singha, Ujjal K.
    Anderson, Judith
    Timm, Michael
    Go, Hai N.
    Lu, Ganwei
    Huston, Alissa
    Ehrlich, Lori A.
    Dimmock, Elizabeth
    Lentzsch, Suzanne
    Hideshima, Teru
    Roodman, G. David
    Anderson, Kenneth C.
    Ghobrial, Irene M.
    CLINICAL CANCER RESEARCH, 2006, 12 (22) : 6826 - 6835
  • [27] An oral proteasome inhibitor for multiple myeloma
    Pratt, Guy
    LANCET ONCOLOGY, 2014, 15 (13): : 1417 - 1418
  • [28] Proteasome inhibitor for treatment of multiple myeloma
    Ahmad, K
    LANCET ONCOLOGY, 2005, 6 (08): : 546 - 546
  • [29] Proteasome inhibitor therapy in multiple myeloma
    Chauhan, D
    Hideshima, T
    Mitsiades, C
    Richardson, P
    Anderson, KC
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 686 - 692
  • [30] Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
    Jin, Hong-Guang
    Wu, Guo-Zhen
    Wu, Guo-Hua
    Bao, Yong-Ge
    ONCOLOGY LETTERS, 2018, 15 (05) : 6257 - 6264
12345